Comparison of the effects of edoxaban, an oral factor Xa inhibitor, and other anticoagulants on thrombin generation

被引：0
|
作者：
Mendell, J. [1 ]
Li, Y. [1 ]
Samama, M. M. [2 ]
Halim, A-B [1 ]
Song, S. [1 ]
Depasse, F. [3 ]
Kunitada, S. [4 ]
机构：
[1] Daiichi Sankyo Pharma Dev, Edison, NJ USA
[2] Hosp Hotel Dieu, Paris, France
[3] Biomnis Lab, Ivry, France
[4] Daiichi Sankyo Co Ltd, Tokyo, Japan
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2011年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P-WE-176
引用
收藏
页码：575 / 575
页数：1
相关论文
共 50 条
  • [31] AN ORAL FACTOR XA INHIBITOR, EDOXABAN, ALLEVIATES DIABETIC NEPHROPATHY IN MICE LACKING eNOS
    Oe, Yuji
    Fushima, Tomofumi
    Sato, Emiko
    Sato, Hiroshi
    Ito, Sadayoshi
    Takahashi, Nobuyuki
    JOURNAL OF HYPERTENSION, 2016, 34 : E102 - E102
  • [32] Impaired carboxylation of osteocalcin by warfarin, but not edoxaban, an oral direct factor Xa inhibitor, in rats
    Morishima, Y.
    Kamisato, C.
    Honda, Y.
    Furugohri, T.
    Shibano, T.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 135 - 136
  • [33] Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment
    Jochen Graff
    Sebastian Harder
    Clinical Pharmacokinetics, 2013, 52 : 243 - 254
  • [34] Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment
    Graff, Jochen
    Harder, Sebastian
    CLINICAL PHARMACOKINETICS, 2013, 52 (04) : 243 - 254
  • [35] Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays
    Gosselin, R.
    Grant, R. P.
    Adcock, D. M.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2016, 38 (05) : 505 - 513
  • [36] Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects
    Matsushima, Nobuko
    Lee, Frank
    Sato, Toshiyuki
    Weiss, Daniel
    Mendell, Jeanne
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2013, 2 (04): : 358 - 366
  • [37] Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: Comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants
    Morishima, Y
    Tanabe, K
    Terada, Y
    Hara, T
    Kunitada, S
    THROMBOSIS AND HAEMOSTASIS, 1997, 78 (05) : 1366 - 1371
  • [38] In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban
    Gerotziafas, G. T.
    Elalamy, I.
    Depasse, F.
    Perzborn, E.
    Samama, M. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (04) : 886 - 888
  • [39] Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants
    Spronk, Henri M. H.
    de Jong, Anne Margreet
    Crijns, Harry J.
    Schotten, Ulrich
    Van Gelder, Isabelle C.
    ten Cate, Hugo
    CARDIOVASCULAR RESEARCH, 2014, 101 (03) : 344 - 351
  • [40] An in-vitro evaluation of direct thrombin inhibitor and factor Xa inhibitor on tissue factor-induced thrombin generation and platelet aggregation: a comparison of dabigatran and rivaroxaban
    Wan, Huaibin
    Yang, Yanmin
    Zhu, Jun
    Wu, Shuang
    Zhou, Zhou
    Huang, Bi
    Wang, Juan
    Shao, Xinghui
    Zhang, Han
    BLOOD COAGULATION & FIBRINOLYSIS, 2016, 27 (08) : 882 - 885
12345